Effects of long-term maintenance therapy with a new glucocorticoid, deflazacort, on mineral metabolism and statural growth.

Deflazacort was substituted for Prednisone (based on the equivalence 1 mg Prednisone equals 1.2 mg Deflazacort), during maintenance glucocorticoid therapy in 9 children, 5 with renal diseases and 4 with connective tissue or immunoproliferative disorders. Six patients received 0.26-0.35 mg/kg body weight (B.W.)/day and 3 0.48-1.2 mg/kg B.W. on alternate days, for 10-16 months. Except for a child with chronic juvenile arthritis, who was also unresponsive to Prednisone, the therapeutic effects of Deflazacort were excellent. Steroid side effects present in 8 patients decreased or disappeared. Plasma Ca, P, Mg, creatinine, alkaline phosphatase, iPTH(1-34), urinary excretion of Ca, cAMP, and TRP remained normal. Plasma iPTH(1-84) remained normal in 5 children; in the other 4 patients it increased from normal to slightly elevated values. On Deflazacort, plasma calcidiol concentrations were within the normal range in 6/8 patients prescribed daily doses of vitamin D2 (1,600-2,400 IU) or calcidiol (20 micrograms). Plasma 1,25(OH)2D levels monitored in 5 children were also normal. The osteoporosis, evaluated on the tibial cortico-diaphyseal ratio and the trabecular aspect of bone radiograms, present in 5 patients, persisted in 1 and improved in the others. On Deflazacort, statural growth proceeded normally in all subjects, with a modest acceleration of growth velocity in 3 children. These results seem encouraging for extending clinical trials with Deflazacort to the active phase of pediatric diseases requiring glucocorticoid.
AuthorsS Balsan, D Stéru, A Bourdeau, R Grimberg, G Lenoir
JournalCalcified tissue international (Calcif Tissue Int) Vol. 40 Issue 6 Pg. 303-9 (Jun 1987) ISSN: 0171-967X [Print] GERMANY, WEST
PMID3111667 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Minerals
  • Parathyroid Hormone
  • Pregnenediones
  • deflazacort
  • Calcifediol
  • Calcium
  • Prednisone
  • Adolescent
  • Anti-Inflammatory Agents, Non-Steroidal
  • Arthritis (drug therapy)
  • Body Height
  • Bone Diseases, Metabolic (chemically induced)
  • Bone and Bones (metabolism)
  • Calcifediol (blood)
  • Calcium (blood)
  • Child
  • Child, Preschool
  • Female
  • Growth Disorders (chemically induced)
  • Humans
  • Kidney Diseases (drug therapy)
  • Male
  • Minerals (metabolism)
  • Parathyroid Hormone (blood)
  • Prednisone (adverse effects, therapeutic use)
  • Pregnenediones (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: